Mineralys Therapeutics (MLYS) Consolidated Net Income (2022 - 2026)

Mineralys Therapeutics has reported Consolidated Net Income for 5 years, with the latest figure at -$45.3 million in Q1 2026.

• Quarterly Consolidated Net Income fell 2.01% year-over-year to -$45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$317.8 million (down 12.93% YoY) and the FY2025 annual result came in at -$316.9 million, down 16.37% from the prior year.
• Consolidated Net Income rose to -$45.3 million in Q1 2026 per MLYS's latest filing, from -$184.6 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$6.5 million in Q2 2022 and troughed at -$184.6 million in Q4 2025.
• A 5-year average of -$44.2 million and a median of -$35.4 million in 2024 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2024 and 2025: Consolidated Net Income sank 360.99% in 2024, then jumped 31.57% in 2025.
• Over 5 years, Consolidated Net Income stood at -$10.2 million in 2022, then tumbled by 180.33% to -$28.6 million in 2023, then tumbled by 360.99% to -$131.7 million in 2024, then tumbled by 40.17% to -$184.6 million in 2025, then surged by 75.44% to -$45.3 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$45.3 million, -$184.6 million, and -$41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.